News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

INVO Bioscience Announces First Shipments of INVOcell Into Bolivia


12/21/2010 7:29:00 AM

BEVERLY, Mass., Dec. 21, 2010 /PRNewswire/ -- INVO Bioscience, Inc. (OTC Bulletin Board: IVOB), a medical device company focused on treatment options for patients diagnosed with infertility, today announced the initial shipments of the INVOcell device into Bolivia. The initial order of INVOcell devices was purchased by The National Center for Fertility and Sterility (CENALFES). Under the direction of clinic director Dr. Joaquin Lopez Arana and embryologist Dr. Patricia Frias, CENALFES is the largest infertility treatment center in Bolivia, having assisted more than 4,000 infertility patients over the past 20 years resulting in more than 1,500 births. Bolivia represents the fourth country in South America where fertility clinics have ordered INVOcell.

Bolivia has approximately 5 fertility centers licensed to perform assisted reproductive procedures. According to the Bolivian Health Ministry there are more than 1.8 million infertile couples in Bolivia, however less than 1,000 couples per year engage in assisted reproductive procedures, largely due to costs. Clinical results have demonstrated outstanding effectiveness of the INVOcell process without many of the inherent expenses associated with traditional in-vitro fertilization (IVF) procedures.

Kathleen Karloff, chief executive officer for INVO Bioscience, commented, "The company continues to execute on its stated goal of introducing the INVOcell device and process to many of the key opinion leaders throughout the world that will influence expanded acceptance and use of our products. CENALFES is one the largest providers of infertility treatments in Bolivia, which we expect to become a strong reference to the exceptional capabilities of INVOcell. We look forward to continue working with the many physicians at CENALFES and elsewhere in Bolivia to offer the many suffering infertile patients a cost effective solution to this very unfortunate problem."

INVOcell is registered as a class II device in Bolivia, and therefore according to local laws does not require extended registration. The company continues to market its products in all applicable countries covered by CE Mark or other local accepted criteria. Additionally, the company has commenced registration processes in China and Ukraine, while continuing to explore additional appropriate countries to begin the registration process to market its products.

INVOcell is CE Mark approved in Europe and Canada and conforms with all consumer health and safety requirements. INVOcell is currently marketed and sold in Austria, Bolivia, Cameroon, Columbia, the Dominican Republic, Guatemala, Nicaragua, Pakistan, Panama, Peru, Spain, Togo, Turkey, and Venezuela.

About INVO Bioscience

INVO Bioscience (IVOB) is a medical device company, headquartered in Beverly, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company's lead product, the INVOcell, is a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman's vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. For more information, please visit www.invobioscience.com.

Private Securities Litigation Reform Act of 1995

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

Kathleen Karloff


INVO Bioscience, Inc.


978-878-9505 ext 504


www.invobioscience.com



SOURCE INVO Bioscience, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES